Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma

被引:16
|
作者
Hillengass, Jens [1 ]
Zechmann, Christian M. [2 ]
Nadler, Andreas [1 ]
Hose, Dirk
Cremer, Friedrich W. [3 ]
Jauch, Anna [3 ]
Heiss, Christiane [4 ,5 ]
Benner, Axel [4 ]
Ho, Anthony D. [1 ]
Bartram, Claus R.
Kauczor, Hans-Ulrich [2 ]
Delorme, Stefan [2 ]
Goldschmidt, Hartmut [1 ,5 ]
Moehler, Thomas M. [1 ]
机构
[1] Univ Heidelberg, Dept Hematol Oncol & Rheumatol, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, Dept Radiol, D-6900 Heidelberg, Germany
[3] Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany
[4] German Canc Res Ctr, Dept Biostat, D-6900 Heidelberg, Germany
[5] Natl Ctr Tumor Dis, Sect Multiple Myeloma, Heidelberg, Germany
关键词
multiple myeloma; monoclonal gammopathy of undetermined significance; dynamic contrast-enhanced magnetic resonance imaging; cytogenetics; in situ fluorescence hybridization;
D O I
10.1002/ijc.23455
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To identify genetic mechanisms controlling bone marrow microcirculation and angiogenesis in patients with plasma cell disease we simultaneously performed bone marrow dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and cytogenetics (iFISH) on CD138 purified plasma cells of MGUS (n = 31) and untreated multiple myeloma (MM) (n = 87) patients. The adverse cytogenetic abnormalities gain of 1q21, deletion 17p13 and deletion 13q14 significantly correlated with at least one DCE-MRI finding (aberrant "focal" microcirculation pattern, increase in median microcirculation parameter Amplitude A or exchange rate constant kep). We conclude that gain of 1q21, deletion 13q14 and deletion 17p13 trigger the angiogenic cascade in MM. Our findings will have important implications for the design, analysis and stratification for clinical studies of patients with MM in particular if compounds with antiangiogenic activity are used. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:2871 / 2875
页数:5
相关论文
共 50 条
  • [31] Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
    Gao, Wen
    Jian, Yuan
    Du, Juan
    Li, Xiaozhe
    Zhou, Huixing
    Zhang, Zhiyao
    Yang, Guangzhong
    Wang, Guorong
    Tian, Ying
    Li, Yanchen
    Wu, Yin
    Fu, Weijun
    Li, Juan
    Chen, Wenming
    CANCER MEDICINE, 2020, 9 (21): : 7819 - 7829
  • [32] Efficacy Analysis of Bortezomib Combined with Lenalidomide in Newly Diagnosed Multiple Myeloma with 1q21 Gain/Amp
    Zhou, Qiaolin
    Wen, Jingjing
    Xu, Fang
    Yue, Jing
    Zhang, Ya
    Su, Jing
    Liu, Yiping
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [33] The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
    Tang, Hoi Ki Karen
    Fung, Chi Yeung
    Morgan, Gareth J.
    Kumar, Shaji
    Siu, Lisa
    Alvin, Ho Wan
    Yip, Sze Fai
    Lau, Ka Ngai Harry
    Lau, Chi Kuen
    Lee, Harold
    Leung, Kwan Hung
    Kho, Bonnie
    Wong, Howard
    Ngai, Cheong
    Hwang, Yu Yan
    Sim, Joycelyn
    Kwong, Yok Lam
    Chim, Chor Sang
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [34] The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma
    Yuanyuan Jin
    Xiaochen Yu
    Jianhua Du
    Hui Li
    Wenjiao Tang
    Congwei Jia
    Yunyan Zan
    Miao Chen
    Yanbin Zhang
    Minhong Yu
    Weiqi Rong
    Daobin Zhou
    Junling Zhuang
    Annals of Hematology, 2021, 100 : 1251 - 1260
  • [35] Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma
    Weinhold, Niels
    Kirn, Desiree
    Seckinger, Anja
    Hielscher, Thomas
    Granzow, Martin
    Bertsch, Uta
    Egerer, Gerlinde
    Salwender, Hans
    Blau, Igor W.
    Weisel, Katja
    Hillengass, Jens
    Raab, Marc S.
    Hose, Dirk
    Goldschmidt, Hartmut
    Jauch, Anna
    HAEMATOLOGICA, 2016, 101 (03) : E116 - E119
  • [36] 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib
    Du, Chenxing
    Mao, Xuehan
    Xu, Yan
    Yan, Yuting
    Yuan, Chenglu
    Du, Xin
    Liu, Jiahui
    Fan, Huishou
    Wang, Qi
    Sui, Weiwei
    Deng, Shuhui
    Fu, Mingwei
    Li, Zengjun
    Li, Chengwen
    Zhao, Jiawei
    Yi, Shuhua
    Liu, Lanting
    Hao, Mu
    Zou, Dehui
    Zhao, Yaozhong
    Qiu, Lugui
    An, Gang
    LEUKEMIA & LYMPHOMA, 2020, 61 (05) : 1201 - 1210
  • [37] The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma
    Jin, Yuanyuan
    Yu, Xiaochen
    Du, Jianhua
    Li, Hui
    Tang, Wenjiao
    Jia, Congwei
    Zan, Yunyan
    Chen, Miao
    Zhang, Yanbin
    Yu, Minhong
    Rong, Weiqi
    Zhou, Daobin
    Zhuang, Junling
    ANNALS OF HEMATOLOGY, 2021, 100 (05) : 1251 - 1260
  • [38] Hepatitis B virus infection and 1q21 amplification in multiple myeloma
    Guo, Dan
    Xu, Peipei
    Guan, Chaoyang
    Xu, Yong
    Yang, Yonggong
    Xu, Jingyan
    Zhou, Rongfu
    Chen, Bing
    ONCOLOGY LETTERS, 2019, 18 (06) : 6196 - 6206
  • [39] ILF2 IS UPREGULATED BY 1Q21 AMPLIFICATION IN MULTIPLE MYELOMA
    不详
    CANCER DISCOVERY, 2017, 7 (08) : 795 - 795
  • [40] Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients
    Grzasko, Norbert
    Hus, Marek
    Pluta, Andrzej
    Jurczyszyn, Artur
    Walter-Croneck, Adam
    Morawska, Marta
    Chocholska, Sylwia
    Hajek, Roman
    Dmoszynska, Anna
    HEMATOLOGICAL ONCOLOGY, 2013, 31 (01) : 41 - 48